Abstract
We report the case of a patient treated with a combination of fludarabine and cyclophosphamide after suffering from B-cell chronic lymphocytic leukemia for 10 years. Three months after treatment, the patient presented with an unusual association, not previously reported in the literature: Richter syndrome (monotypic Epstein-Barr virus- negative large B-cell lymphoma) with the proliferation of Epstein-Barr virus-positive B cells secreting a polytypic immunoglobulin A. The Epstein-Barr virus-positive lymphoproliferation can be accounted for by the type of immunosuppression induced by the treatment.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Cyclophosphamide / administration & dosage
-
Epstein-Barr Virus Infections / etiology*
-
Epstein-Barr Virus Infections / pathology
-
Epstein-Barr Virus Infections / virology
-
Fatal Outcome
-
Herpesvirus 4, Human / isolation & purification
-
Humans
-
Immunoglobulin A / immunology
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
-
Leukemia, Lymphocytic, Chronic, B-Cell / virology
-
Lymphoma, B-Cell / etiology*
-
Lymphoma, B-Cell / pathology
-
Lymphoma, B-Cell / virology
-
Lymphoma, Large B-Cell, Diffuse / etiology*
-
Lymphoma, Large B-Cell, Diffuse / immunology
-
Lymphoma, Large B-Cell, Diffuse / pathology
-
Male
-
Middle Aged
-
Neoplasms, Second Primary
-
Tumor Lysis Syndrome / etiology*
-
Tumor Lysis Syndrome / pathology
-
Tumor Lysis Syndrome / virology
-
Vidarabine / administration & dosage
-
Vidarabine / analogs & derivatives
Substances
-
Immunoglobulin A
-
Cyclophosphamide
-
Vidarabine
-
fludarabine